CNX Therapeutics to expand CNS portfolio through the acquisition of two established brands from SanofiPress Release
CNX Therapeutics is pleased to announce that it has successfully completed the acquisition of two CNS products from Sanofi SA, a global healthcare company.
CNX Therapeutics to expand CNS portfolio through the acquisition of two established brands from EisaiPress Release
CNX Therapeutics has acquired two medicines; Loxapac® (loxapine) and Parkinane LP® (trihexyphenidyl chloride) which are used to treat psychological disorders and Parkinson’s disease respectively.